Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01108731 · ClinicalTrials.gov registry record · Phase 2
The Effect of Milnacipran in Patients With Fibromyalgia
A Phase 2 study of Fibromyalgia, sponsored by Beth Israel Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01108731 is a Phase 2 study of Fibromyalgia that has completed, run by Beth Israel Medical Center. The registered enrollment target is 37 participants, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01108731, a Phase 2 study of Fibromyalgia, has completed, sponsored by Beth Israel Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Milnacipran
Study Locations (1)
New York
- Pain and Fatigue Study Center - Beth Israel Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01108731
The ClinicalTrials.gov registry entry for NCT01108731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (79% lower). The listed sponsor is Beth Israel Medical Center, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01108731 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01108731 about?
NCT01108731 is a clinical study titled "The Effect of Milnacipran in Patients With Fibromyalgia". Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.
What is the current status of trial NCT01108731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2010-03. Estimated completion is 2014-01.
What conditions does trial NCT01108731 study?
This clinical trial studies the following conditions: Fibromyalgia.
What interventions are being tested in trial NCT01108731?
The interventions under investigation include: Placebo (DRUG), Milnacipran (DRUG).
Who is sponsoring clinical trial NCT01108731?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01108731 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nitrous Oxide as Treatment for Fibromyalgia
RECRUITING · Phase 2
-
Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia
COMPLETED · Phase 2
-
Dextromethorphan in Fibromyalgia
COMPLETED · Phase 2
-
Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment
COMPLETED · Phase 2
-
Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain
COMPLETED · Phase 2
-
Heart Rate Variability in Response to Metformin Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.